On this page
What should a bioavailability study report explain?
Explain the availability question, tested formulation and comparator, administration conditions, sampling and analysis that support the exposure conclusion. Preserve product identity and uncertainty throughout the report. Absolute availability, food effect and formulation comparison are related tasks, but their designs, interpretations and CTD placement can differ.
Before you begin
Reporting BA evidence, principally in NDA/IND development. Comparative BE, product-specific recommendations and biologic bridging need their own context.
What you will prepare: A reviewable BA report that connects the tested formulation and conditions to the conclusion actually supported.
Sections covered in this guide (2)
Name the availability question before writing results
Specify whether the study addresses absolute availability, relative availability, formulation proportionality or food effects. These questions can share concentration measurements but need different interpretations. M4E places solid-oral comparisons with an intravenous or oral-liquid reference, formulation proportionality and food-effect BA reports in 5.3.1.1. Comparative BA between similar products, such as clinical and commercial tablets, belongs in 5.3.1.2. The phrase “relative BA” alone does not determine placement; resolve the actual comparator and objective. Section 5.3.1.3 covers in-vitro/in-vivo correlation work.
Obtain the approved protocol, amendments, analysis plan, formulation/batch records, dosing and meal records where relevant, bioanalytical report and final outputs. Confirm the intended use of the report with clinical pharmacology and regulatory colleagues. An unidentified comparator or unknown formulation relationship is an unresolved input, not a detail to infer from the study title.
Make the comparison reproducible
Describe the administered products, doses, routes and treatment periods so a reviewer can reconstruct the comparison. Explain the population, sampling schedule, actual timing, handling of missing or unquantifiable samples, exclusions and the prespecified parameter calculations. Distinguish an observed administration deviation from the analysis decision made about it.
For a food-effect study, identify the tested meal and timing conditions and reconcile them with actual records. For an absolute-BA assessment, make dose normalization and the reference route explicit. Use the study-specific plan and applicable guidance for quantitative criteria; this guide supplies no universal sampling duration, acceptance interval or power calculation.
Keep product identity attached to the exposure statement
Present concentration-time information and the relevant exposure comparisons with analysis populations, uncertainty and evaluability limitations. Explain anomalous profiles, meaningful protocol departures and the effect of missing data. The conclusion should say which formulation, strength and administration conditions were evaluated and what remains untested.
Fictional exercise: a report supports administration of a development capsule after a specified meal. The summary describes the to-be-marketed tablet as unaffected by food. Review the formulation bridge and meal context; if no evidence connects those conditions, narrow the statement and request the missing assessment. A BA result is not automatically a BE conclusion or a dosing instruction.
Reconcile the clinical and quality handoff
Provide an explicit link from report product codes to the formulation and batch descriptions used by the quality team. Match analyte, matrix and method versions to the concentrations used in the analysis. Point the biopharmaceutics summary to the final report and the applicable method evidence rather than retyping a conclusion without its limitations.
If only an in-vitro study exists, explain its role and supporting rationale; do not write a human BA result that was never measured. Before delivery, have a reviewer trace one exposure comparison from the narrative to its table, analysis population and analytical source.
Attach every exposure conclusion to a product and condition
Build the comparison below before transferring the result into a summary or labeling discussion. It prevents a correctly calculated result from being attributed to the wrong product.
| Attribute | Identify for each treatment | Check in the conclusion |
|---|---|---|
| Product | Formulation, batch, strength and code | The same tested product is named |
| Administration | Dose, route, meal and timing as applicable | Conditions are preserved or a bridge is explained |
| Measurement | Analyte, matrix, actual sampling and method | The stated exposure corresponds to that measurement |
| Comparison | Reference, normalization and parameter interval | The conclusion answers the actual study question |
Writing exercise: the result is described as “similar availability,” but the draft omits which parameter and reference support that statement. Replace the broad phrase with the actual comparison and its uncertainty. If the proposed commercial formulation differs, add the separately supported bridge rather than silently changing the product name.
Use the comparative BA/BE guide when the task is an equivalence or formulation comparison. Match the final account to the biopharmaceutics summary and the analytical report it cites.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does the phrase relative bioavailability determine CTD placement?
Not by itself. Examine the actual comparator and objective. M4E distinguishes certain availability comparisons and food-effect work at 5.3.1.1 from comparative BA between similar products at 5.3.1.2. Route the report using that context rather than its abbreviated title.
Does a food-effect result for a capsule apply automatically to a tablet?
No. Preserve the formulation and administration conditions actually tested and identify the evidence connecting them to the proposed product. A change in dosage form or conditions needs an appropriate assessment; a shared active ingredient does not itself establish the bridge.
Can an in-vitro result be reported as measured human bioavailability?
No. Describe the in-vitro experiment and its justified role accurately. A prediction or proposed inference should remain distinct from a human observation. Identify the supporting framework and evidence before claiming that an in-vitro result can serve a particular regulatory purpose.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA M4E(R2): The CTD: Efficacy ↗July 2017, Revision 1, final. Module 5, printed pp.56–64. Organization guidance, not a list of studies required for every application. Reopened September 22, 2026.
Guidance
FDA Bioavailability Studies Submitted in NDAs or INDs ↗April 2022 final. Study-design considerations and in-vitro approaches; NDA/IND scope. Reopened September 22, 2026.
Guidance
FDA M10: Bioanalytical Method Validation and Study Sample Analysis ↗November 2022 final. Scope and section VIII, including Table 1 documentation distinctions. Reopened September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 5.3.1.1. A heading identifies placement, not mandatory applicability.